Clinical Trial

TACE Using Idarubicin Versus Doxorubicin Chemoemulsion in Patients with Hepatocellular Carcinoma

Study acronym: IDADOX
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated January 7, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Little is known about whether the types of chemotherapeutic agents affect the efficacy of transarterial chemoembolization in patients with hepatocellular carcinoma. Although doxorubicin is the most commonly-used chemotherapeutic agent in the world, idarubicin is recently in the spotlight after promising results of the in vitro and prospective single-arm studies. On the other hand, there are many reports showing that the type of chemotherapeutic agents does not significantly alter the efficacy of transarterial chemoembolization. This is a randomized-controlled trial to show the non-inferiority of idarubicin compared to doxorubicin in patients with hepatocellular carcinoma who receive transarterial chemoembolization as the first-line treatment.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-10-27.
Trial Details
NCT Number NCT06114082
Lead Sponsor Seoul National University Hospital
Collaborators: Guerbet
Conditions Hepatocellular Carcinoma, Liver Cancer
Enrollment 128 participants
Start Date 2023-04-28
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-01-07